Paper36076996
Targeting HDAC6 to Overcome Autophagy-Promoted Anti-Cancer Drug Resistance.
Jo H and 2 others. Int J Mol Sci, 2022. Cited by 24 papers, by iCite.
Cite this record
ConductScience Library. Targeting HDAC6 to Overcome Autophagy-Promoted Anti-Cancer Drug Resistance. Papers, record 36076996. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36076996
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Histone Deacetylase Inhibitors | Major topic |
| Autophagy | |
| Histone Deacetylase 6 | |
| Histone Deacetylases |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 2020R1A2C1006996 | National Research Foundation of Korea | PubMed | ||
| 2022R1F1A1060031 | National Research Foundation of Korea | PubMed | ||
| 2017M3A9G7072417 | National Research Foundation of Korea | PubMed | ||
| BK21 Plus Program | National Research Foundation of Korea | PubMed |
Source PubMed
References163
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23402884 | HDAC6 promotes hepatocellular carcinoma progression by inhibiting P53 transcriptional activity. | FEBS Lett | 2013 | https://conductscience.org/library/papers/23402884 | PubMed |
| 2 | 34073238 | Silencing of Histone Deacetylase 6 Decreases Cellular Malignancy and Contributes to Primary Cilium Restoration, Epithelial-to-Mesenchymal Transition Reversion, and Autophagy Inhibition in Glioblastoma Cell Lines. | Biology (Basel) | 2021 | https://conductscience.org/library/papers/34073238 | PubMed |
| 3 | 29278704 | HDAC6 interacts with PTPN1 to enhance melanoma cells progression. | Biochem Biophys Res Commun | 2018 | https://conductscience.org/library/papers/29278704 | PubMed |
| 4 | 35043615 | Discovery of Novel Histone Deacetylase 6 (HDAC6) Inhibitors with Enhanced Antitumor Immunity of Anti-PD-L1 Immunotherapy in Melanoma. | J Med Chem | 2022 | https://conductscience.org/library/papers/35043615 | PubMed |
| 5 | 33611641 | Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer-T cell coculture models. | Gastric Cancer | 2021 | https://conductscience.org/library/papers/33611641 | PubMed |
| 6 | 31597938 | Author Correction: Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. | Sci Rep | 2019 | https://conductscience.org/library/papers/31597938 | PubMed |
| 7 | 33194023 | ΔNp63α promotes the expression and nuclear translocation of PTEN, leading to cisplatin resistance in oral cancer cells. | Am J Transl Res | 2020 | https://conductscience.org/library/papers/33194023 | PubMed |
| 8 | 35541921 | Toosendanin, a novel potent vacuolar-type H+-translocating ATPase inhibitor, sensitizes cancer cells to chemotherapy by blocking protective autophagy. | Int J Biol Sci | 2022 | https://conductscience.org/library/papers/35541921 | PubMed |
| 9 | 32328646 | Increased activation of HDAC1/2/6 and Sp1 underlies therapeutic resistance and tumor growth in glioblastoma. | Neuro Oncol | 2020 | https://conductscience.org/library/papers/32328646 | PubMed |
| 10 | 35348191 | Ricolinostat enhances adavosertib‑induced mitotic catastrophe in TP53‑mutated head and neck squamous cell carcinoma cells. | Int J Oncol | 2022 | https://conductscience.org/library/papers/35348191 | PubMed |
| 11 | 34976139 | MicroRNA-141-3p inhibits the progression of oral squamous cell carcinoma via targeting PBX1 through the JAK2/STAT3 pathway. | Exp Ther Med | 2022 | https://conductscience.org/library/papers/34976139 | PubMed |
| 12 | 34548333 | Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers. | Cancer Res | 2021 | https://conductscience.org/library/papers/34548333 | PubMed |
| 13 | 33452951 | HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells. | Breast Cancer Res Treat | 2021 | https://conductscience.org/library/papers/33452951 | PubMed |
| 14 | 33807514 | Overexpression of Human ABCB1 and ABCG2 Reduces the Susceptibility of Cancer Cells to the Histone Deacetylase 6-Specific Inhibitor Citarinostat. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/33807514 | PubMed |
| 15 | 35109908 | HDAC6 involves in regulating the lncRNA-microRNA-mRNA network to promote the proliferation of glioblastoma cells. | J Exp Clin Cancer Res | 2022 | https://conductscience.org/library/papers/35109908 | PubMed |
| 16 | 27846885 | Autophagy is associated with chemoresistance in neuroblastoma. | BMC Cancer | 2016 | https://conductscience.org/library/papers/27846885 | PubMed |
| 17 | 28529458 | Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer. | Int J Biol Sci | 2017 | https://conductscience.org/library/papers/28529458 | PubMed |
| 18 | 34485153 | Aggresome-Autophagy Associated Gene HDAC6 Is a Potential Biomarker in Pan-Cancer, Especially in Colon Adenocarcinoma. | Front Oncol | 2021 | https://conductscience.org/library/papers/34485153 | PubMed |
| 19 | 34359849 | PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs. | Cells | 2021 | https://conductscience.org/library/papers/34359849 | PubMed |
| 20 | 34969757 | Blockade of GRP78 Translocation to the Cell Surface by HDAC6 Inhibition Suppresses Proliferation of Cholangiocarcinoma Cells. | Anticancer Res | 2022 | https://conductscience.org/library/papers/34969757 | PubMed |
Cited by19
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42769600 | Stress granule phase transitions and neuronal fate in cerebral ischemia-reperfusion injury. | Front Mol Neurosci | 2026 | https://conductscience.org/library/papers/42769600 | PubMed |
| 42709275 | USP19 facilitates CSE-induced cell damage and ferroptosis in chronic obstructive pulmonary disease by deubiquitinating HDAC6 to drive PRDX6 deacetylation. | Immunol Res | 2026 | https://conductscience.org/library/papers/42709275 | PubMed |
| 42304413 | SMC4 is a hypoxia-responsive driver of pulmonary arterial hypertension through an HIF-1α-HDAC6-p21 regulatory axis. | Respir Res | 2026 | https://conductscience.org/library/papers/42304413 | PubMed |
| 42040768 | From EGFR PTM network to TKI resistance: spatial subtypes and targeting in lung cancer. | Cancer Drug Resist | 2026 | https://conductscience.org/library/papers/42040768 | PubMed |
| 41912620 | Piroctone olamine promotes BECN1 transcription and activates autophagy by targeting HDAC6 in colorectal cancer. | Acta Pharmacol Sin | 2026 | https://conductscience.org/library/papers/41912620 | PubMed |
| 41783166 | Histone deacetylases: Function in tumor development and therapeutic prospects (Review). | Oncol Lett | 2026 | https://conductscience.org/library/papers/41783166 | PubMed |
| 41686481 | Structure-activity insights and molecular modeling approaches of anti-TNBC agents: a comprehensive systematic review. | Future Sci OA | 2025 | https://conductscience.org/library/papers/41686481 | PubMed |
| 41498889 | Role of HDAC6 in carcinomas. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41498889 | PubMed |
| 41058704 | The regulatory mechanisms and treatment of HDAC6 in immune dysregulation diseases. | Front Immunol | 2025 | https://conductscience.org/library/papers/41058704 | PubMed |
| 40400020 | CircPRDM5-mediated regulation of miR-433-3p and HDAC6 in Parkinson's disease: a novel neuroprotective axis. | J Transl Med | 2025 | https://conductscience.org/library/papers/40400020 | PubMed |
| 39933949 | A Novel Histone Deacetylase 6 Inhibitor, 4-FHA, Improves Scopolamine-Induced Cognitive and Memory Impairment in Mice. | Biomol Ther (Seoul) | 2025 | https://conductscience.org/library/papers/39933949 | PubMed |
| 39821335 | WT161, a selective HDAC6 inhibitor, decreases growth, enhances chemosensitivity, promotes apoptosis, and suppresses motility of melanoma cells. | Cancer Chemother Pharmacol | 2025 | https://conductscience.org/library/papers/39821335 | PubMed |
| 39800760 | Combinatorial functionomics identifies HDAC6-dependent molecular vulnerability of radioresistant head and neck cancer. | Exp Hematol Oncol | 2025 | https://conductscience.org/library/papers/39800760 | PubMed |
| 39215288 | Writers, readers, and erasers RNA modifications and drug resistance in cancer. | Mol Cancer | 2024 | https://conductscience.org/library/papers/39215288 | PubMed |
| 39155390 | HDAC6 inhibition disrupts HDAC6-P300 interaction reshaping the cancer chromatin landscape. | Clin Epigenetics | 2024 | https://conductscience.org/library/papers/39155390 | PubMed |
| 39063958 | Selective HDAC6 Inhibition Has the Potential for Anti-Cancer Effect in Renal Cell Carcinoma. | J Pers Med | 2024 | https://conductscience.org/library/papers/39063958 | PubMed |
| 38920983 | HDAC9 and miR-512 Regulate CAGE-Promoted Anti-Cancer Drug Resistance and Cellular Proliferation. | Curr Issues Mol Biol | 2024 | https://conductscience.org/library/papers/38920983 | PubMed |
| 38576491 | Novel mechanistic study of HDAC6 regulation of rheumatoid arthritis via CMA: exploring potential therapeutic targets. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/38576491 | PubMed |
| 37938149 | A neural network model was constructed by screening the potential biomarkers of aortic dissection based on genes associated with pyroptosis. | Aging (Albany NY) | 2023 | https://conductscience.org/library/papers/37938149 | PubMed |
Genes103
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36076996
GET https://conductscience.org/api/papers/v1/36076996/references?page=2